The United States of America, as Represented by the Secretary, Department of Health and Human Services

The United States of America as Represented by the Department of Health

New York University

The United States of America as Represented by the Secretary of Health

The United States of America as Represented by the Secretary, Department

Louis H Miller

John B Robbins

Rachel Schneerson

Joanna Kubler-Kielb

Kim Lee Sim

Thomas E Wellems

Fathy Majadly

Chetan Chitnis

David S Peterson

Xin-Zhuan Su

Jay A Berzofsky

David C Kaslow

Ruth S Nussenzweig

Jerry Lee Keith

John H Adams

Darrell T Liu

Christopher P Mocca

Zuzana Biesova

Yimin Wu

Xiangdong Fang

Joseph Stork Smith

Nobutaka Fujii

Richard W Carter

Bruno Pouvelle

Artur Scherf

Pierre Buffet

Michael A Good

Prakash Srinivasan

Benoit Gamain

Dror I Baruch

Christine Scheidig

Jurg Gysin

Michael F Good

Sanjai Kumar

Disclosed is a vaccine comprising an immunogenic composition comprising a complex of AMA1 and RON2 (or a fragment thereof), which elicits an immune response to aspecies in a subject upon administration. The resulting immune response is sufficient to impede or prevent infection by aspecies.

Vaccine comprising AMA1 and RON2

Disclosed are immunogenic conjugates which elicit an immune response toproteins. In particular examples, theproteins include sexual stage surface proteins, circumsporozoite protein (CSP), or immunogenic portions of CSP. Also provided herein are immunogenic compositions including one or more of the disclosed immunogenic conjugates and a pharmaceutically acceptable carrier. Further provided is a method of eliciting an immune response toin a subject, comprising administering to the subject an immunogenic composition disclosed herein.

Multicomponent vaccine for malaria providing long-lasting immune responses against plasmodia

Conjugates of ookinete surface protein Pfs25 are provided that are efficacious as vaccines against, the most severe form of malaria. Conjugates of ookinete surface protein Pvs25 for use as a vaccine againstare also provided. Methods for preparing the conjugates, which comprise the ookinete surface protein bound onto itself or onto another protein by a linking group, are also provided.

[object Object]

The present invention provides isolated polypeptides useful in the treatment and prevention of malaria caused byor. In particular, the polypeptides are derived from the binding domains of the proteins in the EBL family as well as the sialic acid binding protein (SABP) onmerozoites. The polypeptides may also be derived from the Duffy antigen binding protein (DABP) onmerozoites.

Binding domains from Plasmodium vivax and Plasmodium falciparum erythrocyte binding proteins

The present invention relates to the discovery of a var gene and corresponding protein that modulates adhesion of parasitized red blood cells to chondroitin sulfate A. Novel biological tools, prophylactics, therapeutics, diagnostics, and methods of use of the foregoing are also disclosed.

Identification of the domain of Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) that mediates adhesion to chondroitin sulfate A

The present invention provides isolated polypeptides useful in the treatment and prevention of malaria caused by or . In particular, the polypeptides are derived from the binding domains of the proteins in the EBL family as well as the sialic acid binding protein (SABP) on merozoites. The polypeptides may also be derived from the Duffy antigen binding protein (DABP) on merozoites.

Binding domains from plasmodium vivax and plasmodium falciparum erythrocyte binding proteins

The present invention provides isolated polypeptides useful in the treatment and prevention of malaria caused by Plasmodium falciparum or P. vivax. In particular, the polypeptides are derived from the binding domains of the proteins in the DBL family as well as the sialic acid binding protein (SABP) on P. falciparum merozoites. The polypeptides may also be derived from the Duffy antigen binding protein (DABP) on P. vivax merozoites.

Binding domains from plasmodium vivax and plasmodium falciparum

The present invention provides isolated polypeptides useful in the treatment and prevention of malaria caused by Plasmodium falciparum or P. vivax. In particular, the polypeptides are derived from the binding domains of the proteins in the EBL family as well as the sialic acid binding protein (SABP) on P. falciparum merozoites. The polypeptides may also be derived from the Duffy antigen binding protein (DABP) on P. vivax merozoites.

Binding domains from Plasmodium vivax and Plasmodium falciparum

The present invention relates to DNA segments encoding the Duffy receptor of a Plasmodium parasite, the recombinant DNA and to recombinantly produced Duffy receptor. The Duffy receptor can be utilized as a vaccine for humans against malaria.

Plasmodium vivax and Plasmodium knowlesi Duffy receptor

DNA encoding Plasmodium vivax and Plasmodium knowlesi Duffy receptor

A purified peptide which induces proliferation or activation of cytotoxic T cells specifically against circumsporozoite protein of P. falciparum is described. The peptide has an amino acid sequence KPKDELDYENDIEKKICKMEKCS in single letter amino acid code.

Synthetic vaccine against P. falciparum malaria

The circumsporozoite (CS) protein of Plasmodium falciparum has been analyzed to develop a new anti-sporozoite malarial vaccine. Localization of sites for T-cell recognition on this molecule is critical for vaccine design. By using an algorithm designed to predict T-cell sites and a large panel of H-2 congenic mice, a major nonrepetitive T-cell was located. When a synthetic peptide corresponding to this site was covalently linked to the major B-cell site on the molecule, an immunogen capable of eliciting a high titer antibody response was formed. This peptide sequence is capable of priming helper T-cells for a secondary response to the intact CS protein. This site represents the first helper T-cell site described for the CS molecule outside of the repetitive region, and is a major immunodominant T-site on the molecule. The approach described herein is useful in the rational design and construction of more efficacious vaccines.

Malarial immunogen

Monoclonal antibodies have been developed that bind with one or more proteins located on the surface of gametes or zygotes of malaria parasites. These antibodies are specific for antigens on mosquito midgut stages of malaria parasite and sterilize the parasites in mosquitoes otherwise capable of transmitting the disease. The monoclonal antibodies are specific for the 255, 59 and 53 kilodalton surface proteins on Plasmodium falciparum and for the 25 kilodalton surface protein on zygotes and ookinetes of Plasmodium gallinaceum.

Monoclonal antibodies which block infectivity of malarial parasites to

Growing community of inventors

Bethesda, MD, United States of America

Louis H Miller